SCHEMBL7444379

SCHEMBL7444379

CCC(Cc1cc(O)c(C(c2cccc(NS(=O)(=O)c3cn(C)cn3)c2)C2CC2)c(=O)o1)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.39
KDM4E B2RXH2 1/20 0.37
HSD17B1 P14061 2/20 0.35
HSD17B2 P37059 2/20 0.35
LMNA P02545 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
CCR2 P41597 1/20 0.34
KMT2A Q03164 1/20 0.34
ADRA1A P35348 2/20 0.34
ADRA1D P25100 1/20 0.34
ADRA1B P35368 1/20 0.34
SSTR5 P35346 1/20 0.34
GAA P10253 1/20 0.33
HTR6 P50406 1/20 0.33
TRIM24 O15164 2/20 0.33
TSHR P16473 1/20 0.33
MLNR O43193 1/20 0.32
NR1I2 O75469 1/20 0.32
ABCB11 O95342 1/20 0.32
PGR P06401 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7444384 0.89 PARP1 (0.40) PARP1KDM4EHSD17B1HSD17B2LMNA
SCHEMBL7395312 0.88 MLNR (0.35) LMNAADRA1AGAATSHRMLNR
SCHEMBL7451608 0.87 KDM4E (0.36) PARP1KDM4EHSD17B1HSD17B2LMNA
SCHEMBL7405781 0.86 MLNR (0.35) ADRA1AMLNRNR1I2ABCB11PGR
SCHEMBL7445404 0.86 PARP1 (0.37) PARP1KDM4EHSD17B1HSD17B2LMNA
SCHEMBL7401144 0.86 PARP1 (0.37) PARP1KDM4EHSD17B1HSD17B2LMNA
SCHEMBL7401381 0.86 PARP1 (0.37) PARP1KDM4EHSD17B1HSD17B2LMNA
SCHEMBL7398506 0.86 PARP1 (0.37) PARP1KDM4EHSD17B1HSD17B2LMNA
SCHEMBL7403423 0.85 PTPN1 (0.35) KCNK3
SCHEMBL7403117 0.85 HTR6 (0.34) ADRA1AHTR6MLNRNR1I2ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210246125-A1 PYRANONE COMPOUNDS USEFUL TO MODULATE OMA1 PROTEASE 712 NORTH INC. 2021-08-12 US claimed
US-6169181-B1 HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITORS PHARMACIA & UPJOHN COMPANY 2001-01-02 US claimed
EP-0758327-A1 PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1997-02-19 EP claimed
WO-1995030670-A2 PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1995-11-16 WO claimed
US-6169181-B1 HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITORS PHARMACIA & UPJOHN COMPANY 2001-01-02 US disclosed
US-5852195-A Pyranone compounds useful to treat retroviral infections PHARMACIA & UPJOHN COMPANY (US) 1998-12-22 US disclosed
WO-1995030670-A2 PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 1995-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210246125-A1 PYRANONE COMPOUNDS USEFUL TO MODULATE OMA1 PROTEASE OPA1, OLA1, PITRM1 PARP1 1142/4885KDM4E 3676/4885HSD17B1 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.